Search Results
Search this site
66 results found
- About Us | Sequential
Why leading personal care and pharma teams choose Sequential. Meet the award-winning scientists behind our end-to-end clinical research and multi-omics. We are a Team of Award-Winning Scientists Creating a World of Healthier Individuals Our platform is the result of our team’s combined expertise in genetics, epigenetics, and microbiome research. We utilise deep molecular analysis and next-generation sequencing (NGS) technology to understand the impact of product usage on an individual’s microbiome. Through our efforts, we hope to revolutionise the way in which the industry develops and tests its products to deliver optimal results to those utilising them. Our Mission Sequential is the industry leader in clinical human research and testing offering a comprehensive end-to-end platform designed to bring science-backed solutions to the personal care and pharmaceutical industry. Our mission is to understand the impact of the microbiome on the host (humans) and how the host impacts the microbiome in order to characterise human health fully. We offer an extensive platform to conduct research on personal care products through microbiome testing, and biophysical assessments, and offer full recruitment services for studies. We are keen to publish our findings with our partners to increase the literature within this space. At present our database of over 20,000 human microbiome samples is one of the most sophisticated within the industry and is growing rapidly. Innovation Pioneering the forefront of biological science, we consistently introduce groundbreaking advancements to redefine industry standards. Transparency Our commitment to openness ensures a clear understanding of our human microbiome testing processes and analysis. Reliability We guarantee dependable results, fostering trust in the accuracy of our analyses. Our Team at Sequential Oliver Worsley, PhD CHIEF EXECUTIVE OFFICER & CO-FOUNDER Albert Dashi, PhD CHIEF SCIENCE OFFICER & CO-FOUNDER Pétronille Houdart, PharmD SKINCARE DIRECTOR The Commercial Team Derek Butler, PhD MBA COMMERCIAL DIRECTOR Carla Brown, PhD, MBA SALES ASSOCIATE Marya Ahmed, MSc HEAD OF MARKETING Athena Hajaig, BSc MARKETING ASSOCIATE The Scientific Team Sibora Peca, MSc CLINICAL OPERATIONS LEAD Omera Bi, PhD, AFHE R&D PROJECT SPECIALIST Paola Lasluisa, MSc LABORATORY TECHNICIAN Grace Robinson, MSc ASSOCIATE SCIENTIST Khanh Lê Đào, BA JUNIOR CLINICAL ASSISTANT Behafarid Ghalandari, PhD SENIOR AI SCIENTIST Omololu Fagunwa, PhD SENIOR BIOINFORMATICIAN Sanjana Joshi, MSci JUNIOR CLINICAL ASSISTANT Amir Jassim, PhD SENIOR COMPUTATIONAL BIOLOGIST Sija Sajibu, PhD SENIOR SCIENTIST Ami Picari CLINICAL ASSISTANT Please find listed a selection of relevant peer-reviewed publications from our advisors. Wu G, TL Dawson, et al. (2015) Genus-Wide Comparative Genomics of Malassezia Delineates Its Phylogeny, Physiology, and Niche Adaptation on Human Skin. PLOS Genetics 11(11): e1005614. Chng, K., Nagarajan, N., et al. (2016) Whole metagenome profiling reveals skin microbiome-dependent susceptibility to atopic dermatitis flare. Nat Microbiol 1, 16106. Tay, A.S., Nagarajan, N., et al (2018). 1039 Skin microbiome profiles of atopic dermatitis patients segregate into two community composition types that are stable before and after therapy. Journal of Investigative Dermatology. 138. S176. 10.1016/j.jid.2018.03.1051. Ramasamy S., Barnard, E., Dawson, TL, and Huiying Li. (2019). Role of the skin microbiota in acne pathophysiology. British Journal of Dermatology, https://doi.org/10.1111/bjd.18230. Dawson, TL. (2019) Malassezia: The Forbidden Kingdom Opens. Cell Host Microbe https://doi.org/10.1016/j.chom.2019.02.010 Tay, A.S., Nagarajan, N., et al (2020). Atopic dermatitis microbiomes stratify into ecologic dermotypes enabling microbial virulence and disease severity. The Journal of allergy and clinical immunology. 10.1016/j.jaci.2020.09.031. Dawson, TL. (2021) Malassezia: A Skin Commensal Yeast Impacting Both Health and Disease. Front. Cell. Infect. Microbiol., doi.org/10.3389/fcimb.2021.659219 Bissonnette, Robert & FAAD, & Palijan, Ana & Salem, Youssef & Maari, Catherine & Proulx, Etienne & Edjekouane, Lydia & Joly-Chevrier, Maxine & Devis, Andrew & Dashi, Albert & Worsley, Oliver. (2024). 50694 Gut microbiome differences between patients with moderate to severe Chronic Hand Eczema and healthy subjects. Journal of the American Academy of Dermatology. 91. AB224. 10.1016/j.jaad.2024.07.889. Supported By: Scientific Board of Advisors Our advisors are world leaders in the skin microbiome and have extensive experience in bringing forward solutions for skin concerns Prof. Tom Dawson Senior Principal Investigator at Skin Research Institute of Singapore. Over 30 years experience in biotechnology innovations, and expert in the skin and hair microbiome. Doctor of Philosophy (PhD), Pharmacology at the Univer sity of North Carolina. Dr Kimberly Capone Dr Kimberly Capone is a pioneer and established expert in microbiology and the human microbiome field where she created new business opportunities across multiple brands over 13 years at Johnson & Johnson Consumer, Inc. Areas of concentration included infant and adult skin, vaginal, gut, and oral health. Prof. Phillip Bennett Phillip Bennett is Professor of Obstetrics and Gynaecology and Director of the Institute of Reproductive and Developmental Biology. Professor Bennett has been one of the key pioneers in researching the vaginal microbiome. In particular, to understand and characterise the impact of the vaginal microbiome on preterm labour. Bennett has published over 400 peer-reviewed research articles over his career. Dr Natalya Fox Dr Natalya Fox is a Dermatologist at the NHS - St George's Hospital, London. Previously, Fox did her MBChB at the University of Edinburgh 201 4 and has her Full MRCP UK in Dermatology. Fox is passionate about the skin microbiome and its place in dermatology. Prof. Elena Lurie-Luke A senior R&D, Innovation and Entrepreneurship Executive with extensive technical, strategic business development. Proven leadership experience in both global FMCG and public health sector environments. Prof. Niranjan Nagarajan Associate Director & Senior Group Leader at Genome Institute of Singapore. Expert in computation biology, in particular the study of microbial communities resident on the human skin. Doctor of Philosophy (PhD), Computer Science at Cornell University. Dr Alexander Lezhava Senior Group Leader & Associate Director at Genome Institute of Singapore. Expert in the commercial development of medical diagnostics and clinical-grade molecular assays. Doctor of Philosophy (PhD), Microbiology at Hiroshima University. Supporting Global Studies Our Labs Sequential has clinical testing labs in New York City, Cambridge, and Singapore. Being close to our customers has allowed us to reduce turnaround time while retaining intellectual property in-house. Cambridge Lab Moneta Building Babraham Research Campus, Cambridge CB22 3AT New York Lab Sequential (SOSV) 7 Penn Plaza, 9th Fl, New York NY 10001 Singapore Lab Astar Central 79 Ayer Rajah Crescent, Singapore 139955 Supporting World-Class Clients & Partners
- Thank You | Sequential
We will review your query and get back to you within 1-2 business days. Thank you for getting in touch! We will review your query and get back to you within 1-2 business days.
- Ingredients | Sequential
The ingredient list for our Biome Mask formulation with each of their applications from giving deep hydration to protecting from pollutants with antioxidant benefits. Category Ingredient What is it? Benefit Melanin Targeters Arbutin Arbutin is an antioxidant that is extracted from different berries. Arbutin helps in ensuring that skin is brightened and pigmentation is reduced in the skin. It can also fade scars. Hydrators Squalane Squalane is a hydrogenated version of squalene. It is an emollient and behaves similar to our own skin sebum. Prevents moisture loss, can neutralize UV damage . Postbiotics Lactobacillus ferment Lactobacillus ferment is a non-living probiotic ingredient made by fermentation of the microorganism Lactobacillus. Thanks to its soothing effect on the skin, it helps to strengthen the skin's defense and maintains the health of the skin microbiome. Allantoin Allantoin is an extract from comfrey plant. Allantoin protects and soothes the skin. Trehalose Trehalose is a disaccharide with hydrating properties for the skin. It’s a plant sugar. Trehalose is used as a prebiotic and is effective to help maintain healthy skin. Green Tea Extract Extract from the leaves of green tea. Tea Extracts is an antioxidant ingredient that aids soothing the skin and can also address skin discoloration and early signs of aging. Colloidal Oatmeal Colloidal Oatmeal is cocktail of oats that has been refined into powder and acts as a skin protectant. Colloidal Oatmeal aids in locking in moisture in the skin barrier and also has soothing properties. Skin Soothing Multi-Ceramide [Ceramide NP; Phytosphingosine] Ceramides are lipids or fats that exist in skin cells and make up to 40% of your outer skin layer. Ceramides are crucial in aiding your skin to retain moisture and prevent unwanted bacteria from entering your body. Skin Repairing Peptide Complex [copper tripeptide-1, Acetyl heaxapeptide-8, Palmitoyl Pentapepdide-4, Palmitoyl tripeptide-1, Palmitoyl tetrapepide-7, tripeptide-1, tripeptide-2, tripeptide-2, tripeptide-3, acetyl Octapeptide 3] Peptides are amino acid chains that aid in the forming of certain types of protein in the skin such as elastin and collagen. Peptides can help in increasing skin elasticity and reducing signs of aging, allowing skin to appear firmer. Skin Shields Vitamin E [Tocopherol] Tocopherol is an excellent example of a powerful antioxidant that is oil-soluble, meaning it can easily dissolve into the skin. Tocopherol helps in combating free-radical damage (such as pollution), and can also be an effective hydrator. Retinyl Palmitate Retinyl Palmitate is the most abundantly used form of retinol (Vitamin A). Retinyl Palmitate has anti-aging properties as well as anti-oxidant properties. Centella Asiatica Centella Asiatica is a medicinal herb that is known to treat inflammation and has antioxidant properties. Centella Asiatica is used as an active ingredient in skincare products for anti-inflammation, anti-oxidant and soothes compromised skin.
- Terms and Conditions | Sequential
Understand Sequential's terms and conditions for using our website. Terms Of Use Last updated: July 28, 2026 These Terms of Use govern access to and use of the website at sequential.bio (the Site), operated by Sequential Skin Ltd, a company registered in England and Wales under company number 12547483, with its registered office at Moneta (B280), Babraham Research Campus, Babraham, Cambridgeshire, CB22 3AT, United Kingdom. These terms apply to the Site only. They do not govern laboratory, testing, research, recruitment, software, app, product-supply or other services, which may be subject to separate contracts, study documents, participant information or additional terms. 1. Acceptance of these terms By using the Site, you confirm that you accept these Terms of Use and will comply with them. If you do not agree, you must not use the Site. If you use the Site on behalf of an organisation, you confirm that you are authorised to do so. 2. Information about us The Site is operated by Sequential Skin Ltd. Our registered office and principal legal contact address is Moneta (B280), Babraham Research Campus, Babraham, Cambridgeshire, CB22 3AT, United Kingdom. Our company number is 12547483. You can contact us at team@sequential.bio . 3. Other terms that may apply Our Privacy Policy explains how we handle personal information, and our Cookie Policy explains how cookies and similar technologies are used. Additional terms will apply if you create an account, use an app or portal, purchase or receive services, apply for a role, or take part in a study or testing programme. Privacy Policy: sequential.bio/privacy-policy Cookie Policy: sequential.bio/cookiepolicy 4. Changes to these terms and the Site We may update these terms from time to time. The date at the top shows when they were last revised. Please check them whenever you use the Site. We may also update, suspend, withdraw or restrict any part of the Site for business, legal, security or operational reasons. We do not guarantee that the Site, or any content on it, will always be available or uninterrupted. 5. Accounts and security If any part of the Site requires an account or access credentials, you must provide accurate information, keep your credentials confidential, and tell us promptly if you suspect unauthorised access. You are responsible for activity carried out through your account unless caused by our breach of duty. We may suspend or disable credentials where reasonably necessary to protect users, systems or data, or where these terms are breached. 6. Permitted use You may use the Site for lawful purposes, including learning about Sequential, contacting us and accessing materials we make available. You may print or download extracts for your internal, non-commercial reference, provided you do not alter them or remove ownership notices. 7. Prohibited use You must not: use the Site unlawfully, fraudulently or in a way that infringes another person's rights; introduce malware, harmful code or material designed to disrupt, damage or gain unauthorised access to systems or data; attempt to bypass security, access controls, rate limits or technical restrictions; scrape, crawl, harvest or use automated means to access the Site except as permitted by law, by a published robots instruction, or with our written permission; copy, reproduce, modify, distribute, sell or commercially exploit Site content except as expressly permitted by these terms or by law; misrepresent your identity or affiliation, or submit information you do not have the right to provide; or use the Site to transmit unsolicited marketing, abusive material or content that is defamatory, discriminatory, obscene or otherwise unlawful. 8. Intellectual property rights We or our licensors own the intellectual property rights in the Site and its content, including text, graphics, software, branding, databases and know-how. Those rights are protected by law. No rights are granted except the limited right to use the Site under these terms. Sequential names, logos and trade marks may not be used without our prior written permission. Where we identify third-party content or rights holders, their rights remain with them, and any use may be subject to separate terms. 9. Information and materials you provide You remain responsible for information and materials you submit through the Site. You confirm that you are entitled to provide them and that they are accurate to the best of your knowledge. You grant us a limited, non-exclusive right to host, copy and use submitted material only as reasonably necessary to operate the Site, respond to you, provide requested services, comply with law and protect our legitimate interests. Personal information is handled as described in the Privacy Policy and, where applicable, a study-specific notice. 10. No medical, clinical or regulatory advice Site content is provided for general information about our business, technology and services. It is not medical advice, diagnosis or treatment, does not replace advice from a qualified healthcare professional, and is not legal, regulatory or investment advice. Research or scientific content may summarise developing fields and should not be relied on as a guarantee of outcomes, product performance or regulatory acceptance. 11. Accuracy and reliance We use reasonable care in preparing Site content but do not guarantee that it is complete, accurate, current or suitable for a particular purpose. You should obtain appropriate professional advice and independently verify information before acting on it. Statements about planned services, research or capabilities may change. 12. Third-party links and services The Site may link to websites, platforms or services operated by third parties. Links are provided for convenience and do not imply endorsement. We do not control third-party content, availability, security or privacy practices. Your use of third-party services is governed by their own terms and notices. 13. Linking to the Site You may link to public pages in a fair and lawful way that does not damage our reputation or suggest an association, approval or endorsement where none exists. You must not frame the Site or link from unlawful or misleading content. We may withdraw linking permission where reasonably necessary. 14. Security and viruses We take reasonable steps to protect the Site, but we do not guarantee that it will be secure or free from bugs, vulnerabilities or malicious code. You are responsible for configuring your devices and using appropriate security software. You must not misuse the Site by knowingly introducing harmful material or attempting unauthorised access. 15. Our responsibility for loss or damage Nothing in these terms excludes or limits liability where it would be unlawful to do so, including liability for death or personal injury caused by negligence, fraud or fraudulent misrepresentation. If you are a business user, the Site is provided without warranties or conditions except those that cannot lawfully be excluded. To the extent permitted by law, we are not liable for loss of profit, revenue, business, contracts, anticipated savings, data or goodwill, or for indirect or consequential loss, arising from use of or inability to use the Site or reliance on Site content. If you are a consumer, we are responsible for foreseeable loss caused by our breach of these terms or failure to use reasonable care and skill. We are not responsible for loss that was not foreseeable, for business losses, or for loss caused by events outside our reasonable control. Your mandatory consumer rights are not affected. 16. Suspension and termination We may suspend or terminate access where we reasonably believe you have breached these terms, created a security or legal risk, or misused the Site. Provisions that by their nature should continue after access ends, including intellectual property, disclaimers, liability and governing law, will continue to apply. 17. General If we delay enforcing a right, that does not waive it. If any provision is invalid or unenforceable, the remaining provisions continue in effect. These terms do not give rights to anyone other than you and us. We may transfer our rights and obligations as part of a reorganisation, financing, sale or transfer of our business, provided this does not reduce protections that apply to you by law. 18. Governing law and jurisdiction These terms and any non-contractual dispute arising from them are governed by the laws of England and Wales. If you are a business user, the courts of England and Wales have exclusive jurisdiction. If you are a consumer resident elsewhere in the United Kingdom, you may also bring proceedings in the courts of the part of the United Kingdom where you live, and any mandatory local rights continue to apply. Contact Us Questions about these Terms of Use may be sent to: Sequential Skin Ltd (company number 12547483) Moneta (B280), Babraham Research Campus, Babraham, Cambridgeshire, CB22 3AT, United Kingdom Email: team@sequential.bio
- Sun/UV Targeted Panel | Sequential
By conducting in vivo testing, companies can better assess how sunscreen and SPF products interact with the microbiome, ensuring not only UV protection but also the maintenance of a healthy skin barrier. TARGETED SKIN PANEL Sun/UV Targeted Panel 23 Smart Probes ™ Sun/UV Panel Validated targets: Sphingomonas spp, Micrococcus luteus, Malassezia furfur Absolute Quantification End-to-end Service Qet a Quote Unlock the Secrets of UV Exposure with Sequential's Cutting-Edge Microbiome Testing Why Microbiome Testing for SPF Products? According to the Skin Cancer Foundation, about 1 in 5 Americans will develop skin cancer by the age of 70, with UV exposure being one of the most common causes. With the growing awareness of the risks associated with UV damage, in vivo testing for SPF products has become increasingly crucial. The skin microbiome plays a pivotal role in protecting against UV radiation, but excessive sun exposure can disrupt this delicate balance, leading to increased risk for skin cancer and other forms of skin damage. By conducting in vivo testing, companies can better assess how sunscreen and SPF products interact with the microbiome, ensuring not only UV protection but also the maintenance of a healthy skin barrier. This holistic approach is essential to create safer, more effective sun-care products that prevent long-term damage (American Academy of Dermatology). Sequential is leading the way in microbiome testing for the industry. With a specialized focus on skin conditions, we have developed an innovative solution tailored to help you understand the root causes of UV exposure at the microbial level. Our proprietary sequencing panel is designed specifically to offer in-depth analysis of sun-exposed microbiota, giving you the tools to transform skincare solutions. Customized Analysis Tailored insights specific to UV exposure, allowing your R&D team to develop more personalized and effective products. Actionable Data Leverage detailed reports to guide formulation decisions and validate product efficacy with precision. Product Innovation New SPF products or enhancing existing lines, our data helps you create targeted solutions with proven results. Precision Sequencing Target specific microbial communities associated with sun exposure and UV related skin conditions. Smart Probe s ™ Our dedicated team of scientists has developed an innovative method for evaluating the effects of sun exposure and UV radiation on the skin using our Smart Probes™ technology. This proprietary panel features 23 key markers that we’ve identified as having the most significant influence on skin health, particularly in response to UV damage. To further understand the impact of UV radiation on the skin’s microbiome and overall health, we utilize qPCR technology. This advanced technique allows us to accurately measure changes in microbial populations and skin health following sun exposure. By closely analyzing how sun care products interact with these key markers and microbes, companies can develop solutions that not only protect against UV damage but also support the skin’s natural defenses, ensuring long-term skin health and resilience against sun-induced aging and other effects. Sun/UV Panel Targets Sphingomonas Sphingomonas has been shown to be highly resistant to UV irradiation and capable of reducing reactive oxygen species (ROS) levels in human keratinocytes—the predominant cell type in the epidermis. This discovery underscores the important role that members of the skin microbiome, such as Sphingomonas , play in protecting human skin from solar radiation damage. By mitigating oxidative stress caused by UV exposure, Sphingomonas may contribute to healthier skin and potentially enhance the skin's natural defense mechanisms. Harel N, Ogen-Shtern N, Reshef L, Biran D, Ron EZ, Gophna U. Skin microbiome bacteria enriched following long sun exposure can reduce oxidative damage. Res Microbiol. 2023 Nov-Dec;174(8):104138. doi: 10.1016/j.resmic.2023.104138. Epub 2023 Sep 16. PMID: 37722498. Micrococcus luteus Cyanobacteria have shown potential in skin care due to their ability to decrease pigmentation and reduce damage associated with photoaging. According to research, Cyanobacteria on the skin surface can help mitigate these effects by lowering melanin production and protect the skin from oxidative stress, which contributes to the aging process. Skowron K, Bauza-Kaszewska J, Kraszewska Z, Wiktorczyk-Kapischke N, Grudlewska-Buda K, Kwiecińska-Piróg J, Wałecka-Zacharska E, Radtke L, Gospodarek-Komkowska E. Human Skin Microbiome: Impact of Intrinsic and Extrinsic Factors on Skin Microbiota. Microorganisms. 2021 Mar 5;9(3):543. doi: 10.3390/microorganisms9030543. PMID: 33808031; PMCID: PMC7998121. Malassezia furfur Malassezia furfur is a species of yeast commonly found on human skin, often associated with various dermatological conditions. Despite its ability to synthesize a UV-protective substance called pityriacitrin, Malassezia furfur demonstrates high sensitivity to ultraviolet (UV) radiation. Burns EM, Ahmed H, Isedeh PN, Kohli I, Van Der Pol W, Shaheen A, Muzaffar AF, Al-Sadek C, Foy TM, Abdelgawwad MS, Huda S, Lim HW, Hamzavi I, Bae S, Morrow CD, Elmets CA, Yusuf N. Ultraviolet radiation, both UVA and UVB, influences the composition of the skin microbiome. Exp Dermatol. 2019 Feb;28(2):136-141. doi: 10.1111/exd.13854. Epub 2019 Jan 14. PMID: 30506967; PMCID: PMC7394481. Industry Leader in Absolute Quantification Sequential’s Smart Probe ™ qPCR approach to microbiome analysis can resolve species and subspecies, giving statistically significant findings between skin conditions on in vivo human samples, compared to conventional sequencing approaches. Relevant Research Seasonal Shifts in the Skin Microbiome: Exploring Dynamic Changes Across the Year Shedding Light on Summer Sun: Does UV Exposure Affect the Skin Microbiome? Read More Articles
- Study Goals | Sequential
Clinical efficacy, novel claims, mechanism of action and evidence positioning for finished products, powered by human and microbiome biomarkers. Here to tackle all your study goals. Every study starts with a question. Whether you need to prove your formulation works, understand how it works, find something new in your data, or turn your science into a story your consumers understand, we design research around your objectives. Tell us your goals Clinical Efficacy Studies Novel Claims Discovery Mechanism of Action Scientific Marketing Story Robust human evidence Clinical Efficacy Studies Generate robust human evidence to evaluate the efficacy and performance of your product, formulation or therapeutic. Sequential designs and conducts clinical studies using fit-for-purpose endpoints, from biomarkers and microbiome analysis to biophysical and clinical assessments, helping you build evidence around your research objectives. Discover new opportunities within human data Novel Claims Discovery Go beyond validating predefined claims to discover new opportunities within your human data. Sequential uses biomarker and microbiome insights to identify meaningful biological responses, uncover differentiating product benefits and translate scientific findings into novel, evidence-led claims and research directions. Instead of collecting the same tired claims, discover a new scientific story to sell to your end-users. A holistic picture of your forulation Mechanism of Action Understand not just if your formulation works, but how. By measuring molecular and microbial responses in humans, Sequential helps uncover biological pathways and mechanisms of action, connecting clinical outcomes with deeper biological insight to support R&D, product differentiation and therapeutic development. Complex science into actionable development Scientific Marketing Story Transform complex scientific findings into a clear, compelling story around your product or therapeutic. Sequential connects ingredients, biological pathways, biomarkers and clinical outcomes to build evidence-led narratives that translate your science into competitive brand positioning for your products.
- Acne Targeted Panel | Sequential
Acne affects nearly 85% of people between the ages of 12 and 24, with millions worldwide continuing to struggle with breakouts into adulthood (American Academy of Dermatology). TARGETED SKIN PANEL Acne Targeted Panel 23 Smart Probes ™ Acne Panel Validated targets: Cutibacterium acnes acnes (subtype I) Cutibacterium acnes defendens (subtype II), Cutibacterium acnes elongatum (subtype III) Absolute Quantification End-to-end Service Qet a Quote Unlock the Secrets of Acne with Sequential's Cutting-Edge Microbiome Testing Why Microbiome Testing for Acne? Acne affects nearly 85% of people between the ages of 12 and 24, with millions worldwide continuing to struggle with breakouts into adulthood (American Academy of Dermatology). While many individuals turn to over-the-counter products in hopes of finding relief, the reality is that many of these formulations can exacerbate the problem. Without proper testing, products may contain ingredients that disrupt the delicate balance of the skin, leading to irritation, clogged pores, and even more severe acne. Acne isn’t just skin-deep — it’s driven by a delicate balance of microorganisms on the skin. As skincare companies race to meet demand, a lack of microbiome-focused testing means many products fail to address the root microbial causes of acne. Sequential is leading the way in microbiome testing for the industry. With a specialized focus on skin conditions, we have developed an innovative solution tailored to help you understand the root causes of acne at the microbial level. Our proprietary sequencing panel is designed specifically to offer in-depth analysis of acne-associated microbiota, giving you the tools to transform skincare solutions. Customized Analysis Tailored insights specific to acne-prone skin, allowing your R&D team to develop more personalized and effective products. Actionable Data Leverage detailed reports to guide formulation decisions and validate product efficacy with precision. Product Innovation New acne treatments or enhancing existing lines, our data helps you create targeted solutions with proven results. Precision Sequencing Target specific microbial communities associated with acne development and severity. Smart Probe s ™ Our dedicated team of scientists has developed a groundbreaking method for evaluating microbes through our Smart Probes™, a proprietary panel featuring 23 key microbes specifically identified as having the greatest impact on skin health. To further explore the intricate connection between acne and the skin microbiome, we employ qPCR technology. This cutting-edge technique allows us to precisely measure microbial populations on the skin, providing a clearer understanding of how imbalances in the microbiome can contribute to acne breakouts. By carefully analyzing how skincare products interact with both beneficial and acne-causing microbes, companies can create solutions that not only target acne symptoms but also support a healthier, balanced skin microbiome, promoting clearer and more resilient skin. Acne Panel Targets Cutibacterium acnes acnes (Subtype I) Cutibacterium acnes subtype I is a specific strain of the C. acnes bacterium commonly found within sebaceous (oil) glands. This bacterium plays a key role in maintaining skin health by breaking down sebum, and producing fatty acids that prevent harmful pathogens from colonizing. However, certain strains of subtype I are associated with inflammatory conditions like acne vulgaris. While typically harmless, its overgrowth or imbalance in the skin microbiome can trigger immune responses that lead to acne and other skin issues. Spittaels KJ, Ongena R, Zouboulis CC, Crabbé A, Coenye T. Cutibacterium acnes Phylotype I and II Strains Interact Differently With Human Skin Cells. Front Cell Infect Microbiol. 2020 Nov 16;10:575164. doi: 10.3389/fcimb.2020.575164. PMID: 33330124; PMCID: PMC7717938. Cutibacterium acnes defendens (Subtype II) Cutibacterium acnes subtype II is a strain of the C. acnes bacterium, distinct from subtype I, and is found on human skin, primarily in sebaceous areas. While it shares similarities with other subtypes in maintaining skin health by metabolizing sebum, subtype II is less commonly associated with acne development. It has been linked more to opportunistic infections and medical device-related infections rather than inflammatory acne. Subtype II is typically less inflammatory than subtype I and plays a different role in the skin's microbial balance. Cobian N, Garlet A, Hidalgo-Cantabrana C, Barrangou R. Comparative Genomic Analyses and CRISPR-Cas Characterization of Cutibacterium acnes Provide Insights Into Genetic Diversity and Typing Applications. Front Microbiol. 2021 Nov 3;12:758749. doi: 10.3389/fmicb.2021.758749. PMID: 34803983; PMCID: PMC8595920. Cutibacterium acnes elongatum (Subtype III) Cutibacterium acnes subtype III is a less common strain of the C. acnes bacterium, primarily found in deeper skin layers and associated more with opportunistic infections rather than acne. Unlike subtypes I and II, which are typically found on the skin's surface and sebaceous areas, subtype III is linked to post-surgical infections, particularly around medical implants, and is less involved in acne formation. It tends to have lower inflammatory potential, distinguishing it from other C. acnes subtypes in terms of both location and clinical relevance. Dagnelie MA, Khammari A, Dréno B, Corvec S. Cutibacterium acnes molecular typing: time to standardize the method. Clin Microbiol Infect. 2018 Nov;24(11):1149-1155. doi: 10.1016/j.cmi.2018.03.010. Epub 2018 Mar 12. PMID: 29544912. Industry Leader in Absolute Quantification Sequential’s Smart Probe ™ qPCR approach to microbiome analysis can resolve species and subspecies, giving statistically significant findings between skin conditions on in vivo human samples, compared to conventional sequencing approaches. Relevant Research The Skin Lipidome: Understanding Skin, Differently Your Skin Barrier Isn't Working Alone Sebum Metabolomics: Beyond Oil, Towards Insight Read More Articles
- Nutraceuticals Testing | Sequential
Investigate how supplements and ingestible products affect skin, scalp, and intimate biology, with human and microbiome biomarkers. Clinical Testing for Nutraceuticals Generate robust human evidence for beauty supplements, nutraceuticals and ingestible personal care. From efficacy to mechanisms of action, Sequential helps you understand how your formulation affects human health from within. Design your study Compare methods Probiotics Prebiotics Capsules Powders Gummies Drinks Validate your supplement formulations Analysis For All Your Ingestibles Sequential provides cutting-edge testing designed to work with all nutraceuticals, designed for inside-out benefits. We take into account the gut-skin axis to help you discover that your product's desired outcomes are backed by clinical data. Design your study What can we help you prove Build Evidence Around The Questions That Matter Clinical Efficacy Demonstrate measurable product performance. Novel Claims Generate evidence to support differentiated claims. Mechanism of Action Understand how and why your formulation works. Product Differentiation Compare formulations, ingredients or concentrations. What can we measure Go Beyond Traditional Clinical Endpoints Build a deeper picture of supplement response by combining molecular, microbial and biophysical data. Connect systemic biological changes with measurable outcomes and explore mechanisms that traditional endpoints alone may not reveal. Human Biomarkers Measure molecular responses and investigate biological pathways associated with your supplement or ingredient. Find out more Read More Study design Built Around Your Research Question From exploratory biomarker studies to efficacy-focused clinical research, we tailor study design, recruitment, sampling and analysis to your supplement, population and objectives. Design Recruit Collect Analyse Interpret Why Leading Brands Choose Sequential 50,000+ Sample Database 4,000+ Ingredients Database 10,000+ Participant Database What do I do next? Planning a Nutraceuticals Study? Tell us about your product and what you're looking to prove. We'll help you identify the right study design and measurements. Design Your Study Dive Deeper Into Nutraceuticals Check out our collection of scientific papers, peer-reviewed research, and in-depth clinical articles. Inside-out Skincare Jan 29 2 min read Female reproductive tract - Gut axis: everything is connected Oct 2, 2025 3 min read The potential of probiotics in oral microbiome health Sep 24, 2025 2 min read 1 2 3
- Cookie Policy | Sequential
Understand Sequential's cookie policy for using our website. Cookie Policy Last updated: Jul 28, 2026 This Cookie Policy explains how Sequential Skin Ltd uses cookies and similar storage or access technologies on sequential.bio (the Site). We are registered in England and Wales under company number 12547483, with our registered office at Moneta (B280), Babraham Research Campus, Babraham, Cambridgeshire, CB22 3AT, United Kingdom. This policy should be read with our Privacy Policy. The live Cookie Settings tool on the Site provides the most current technical inventory of cookies and similar technologies, including their provider, purpose and duration. 1. What are cookies and similar technologies? Cookies are small text files stored on a browser or device. Similar technologies include pixels, tags, local storage, software development kits and other tools that store information on, or access information from, a device. They may recognise a device, remember choices, secure a session, measure use or support embedded content and advertising. 2. When we ask for consent We use cookies or similar technologies without consent only where permitted by law, such as where they are strictly necessary to provide a service you request, secure the Site, transmit communications or fall within another applicable statutory exception. For optional technologies, including most analytics, advertising and tracking technologies, we ask for consent before they are used. Consent must be given by a clear positive action. Continuing to browse does not by itself amount to consent. You can accept all, reject all or choose categories through the Cookie Settings tool. 3. Categories we use Strictly necessary. These technologies enable core functions such as page delivery, network management, load balancing, consent records, security, fraud prevention and access to requested features. They cannot generally be switched off through our tool because the Site cannot operate securely or respond to your request without them. Functional and preference. These remember choices such as language, region, display settings or previously selected preferences. If disabled, some convenience features may not work as intended. Analytics and performance. These help us understand how visitors use the Site, identify errors and improve content and performance. We use them only where consent is required and has been given, unless a specific legal exception applies. Advertising and targeting. These may measure campaigns, limit repeated adverts, build or use interest profiles, or support advertising on this or other services. They may recognise a browser across sites or services and are used only with required consent. Embedded content and social media. Videos, maps, forms, social media features or other third-party content may set or read technologies when enabled. The provider may use the resulting information under its own privacy terms. We obtain consent where required before activating non-essential embedded technologies. 4. First-party and third-party technologies First-party cookies are set by the Site. Third-party technologies are provided by another organisation, for example an analytics, hosting, video, social media, customer-relationship or advertising provider. Third parties may combine information from the Site with information obtained elsewhere, subject to their own terms and your choices. We do not control how third parties use information independently of us. 5. Current cookie details and duration Cookie names and durations can change when the Site or a provider is updated. The Cookie Settings tool is the authoritative current inventory. For each technology, it should identify: the cookie or technology name; whether it is first-party or third-party and the provider; its category and purpose; the information it stores or accesses where this is not clear from the purpose; and whether it is a session technology or the period before it expires. Session cookies normally expire when the browser closes. Persistent cookies remain until their stated expiry or until they are deleted. We review durations and use no longer than reasonably necessary for the stated purpose. 6. Managing or withdrawing consent You can change or withdraw your choices at any time through the Cookie Settings control on the Site. Withdrawing consent does not affect processing that was lawful before withdrawal. Optional technologies will be disabled for future activity after your choice is applied, although information already shared with a third party may remain subject to that party's retention rules. You can also use browser or device settings to block or delete cookies. Blocking all cookies may prevent parts of the Site from working. Browser deletion may remove the cookie that remembers your choices, so the consent tool may appear again. 7. Personal information Some cookie identifiers, IP addresses and usage information may be personal information. Where they are, our Privacy Policy explains the controller, purposes, lawful bases, recipients, transfers, retention and your rights. Consent under the cookie rules and the lawful basis for any related personal-information processing are considered separately where required. Privacy Policy: sequential.bio/privacy-policy 8. Changes to this policy We may update this policy when our use of technology, providers or legal requirements changes. The date at the top shows the latest revision. Where a change affects consent, we will ask for fresh consent where required. Contact Us Questions about this Cookie Policy or your cookie choices may be sent to: Sequential Skin Ltd (company number 12547483) Moneta (B280), Babraham Research Campus, Babraham, Cambridgeshire, CB22 3AT, United Kingdom Email: team@sequential.bio
- Oral Care Testing | Sequential
Test toothpastes, mouthwashes, gels, lozenges and oral treatments in vivo. Oral health studies with human and microbiome biomarkers and biophysical data. Clinical Testing for Oral Care Formulations Generate robust human evidence for oral care products and therapeutic formulations. From efficacy to mechanisms of action, Sequential helps you understand how your formulation affects oral health in real people. Design your study Compare methods Toothpaste Mouthwash Oral Gel Whitening Gel Oral Spray Moisturiser Targeted Treatments Validate your oral care formulations From Everyday Oral Care to Targeted Treatments Sequential provides cutting-edge in vivo multiomics testing for moisturizers, serums, cleansers, SPF formulations, and beyond. We analyze the complex relationship between the host skin and the microbiome using real people from our global database. Design your study What can we help you prove Build Evidence Around The Questions That Matter Clinical Efficacy Demonstrate measurable product performance. Novel Claims Generate evidence to support differentiated claims. Mechanism of Action Understand how and why your formulation works. Product Differentiation Compare formulations, ingredients or concentrations. What can we measure Go Beyond Traditional Clinical Endpoints Build a deeper picture of oral health by combining molecular, microbial and clinical data. Explore biological response, microbial ecology and mechanisms that traditional endpoints alone may not reveal. Human Biomarkers Measure molecular responses and investigate biological pathways relevant to oral health and your formulation. Find out more Read More Study design Built Around Your Research Question From exploratory microbiome and biomarker studies to efficacy-focused clinical research, we tailor study design, recruitment, sampling and analysis to your formulation, population and objectives. Design Recruit Collect Analyse Interpret Why Leading Brands Choose Sequential 50,000+ Sample Database 4,000+ Ingredients Database 10,000+ Participant Database What do I do next? Planning an Oral Care Study? Tell us about your product and what you're looking to prove. We'll help you identify the right study design and measurements. Design Your Study Dive Deeper Into Oral Care Check out our collection of scientific papers, peer-reviewed research, and in-depth clinical articles. The Effects of Teeth Whitening on the Oral Microbiome Oct 14, 2025 2 min read The potential of probiotics in oral microbiome health Sep 24, 2025 2 min read It’s All Connected: What Does the Oral-Gut Microbiome Axis Mean for Overall Health? Jun 4, 2025 2 min read 1 2 3 4 5
- Dermatological Therapeutics Testing | Sequential
Biomarker-driven clinical evidence for dermatological therapeutics and medicated topicals, from mechanism of action to measurable clinical outcomes. HUMAN BIOMARKERS Prove therapeutic efficacy with biomarker-driven clinical evidence. MICROBIOME BIOMARKERS As a specialised CRO for dermatological therapeutics, we go beyond traditional study execution, delivering biomarker-driven clinical evaluation through validated assays, condition-specific expertise, and rigorous, reproducible methodologies. Prove your product’s impact From what to why Clinical testing vs biological understanding In dermatology, demonstrating safety and efficacy is essential, but often limited by how studies are designed and measured. Many studies rely on broad clinical endpoints or insufficient biomarker depth, making it difficult to: Link outcomes to underlying biological mechanisms Without a robust study design, validated assays, and appropriate candidate selection, even strong formulations risk producing incomplete or inconclusive data. From what to why Clinical evaluation grounded in biology Sequential provides biomarker-driven clinical evaluation for dermatological therapeutics, combining human biomarker profiling, microbiome sequencing, and validated clinical endpoints. By connecting clinical outcomes with underlying biological pathways, we ensure data is biologically meaningful, reproducible, and generated under SOP-controlled conditions. Leveraging extensive internal datasets and condition-specific validated assays, we deliver high-quality, physiologically relevant data suitable for clinical development and regulatory use. Deep experience across key dermatological indications, including acne, atopic dermatitis, rosacea, and ageing-related skin changes. Condition-specific expertise Validated assays & panels SOP-backed, physiologically relevant assays designed for reproducibility, biological meaning, and regulatory alignment. Specialised recruitment Structured participant screening and standardized, non-invasive collection methods to ensure data integrity and scalable study execution. A rigorous, end-to-end clinical framework 2 Specialized Recruitment We can recruit ethnically diverse participants globally using GDPR-compliant, IRB-approved protocols to deliver timely, meaningful results for targeted populations. Our studies are conducted across three clinical testing facilities in New York, Cambridge (UK), and Singapore. Results Sequential Patch 4 Biomarker Discovery In our laboratory, samples undergo stringent processing to generate high-quality data using multi-omics technologies. We capture host and microbial responses from skin sites. 6 Biomarker Packages We design specialised biomarker packages informed by in-depth skin science, delivering relevant, quantifiable data to support therapeutic validation and product development. 1 Study Protocols & Design We collaborate with clients to develop study protocols tailored to their objectives and endpoints Results Recruitment 3 Non-Invasive Collection We ensure standardised, non-invasive sampling with clinically validated systems, delivering reproducible, globally consistent, and statistically robust data. Results Multi-Omics 5 Analysis & Reporting All data analysis and reporting are handled in-house, using controlled pipelines to transform complex multi-omics and sequencing datasets into actionable insights linked to customer endpoints, supporting therapeutic development and mechanistic understanding. Results Discover Packages
- Next Generation of Ingredients & Validation| Sequential
The Future of Next-Generation Ingredients & Validation. A full day for senior R&D, innovation and scientific leaders across beauty, personal care and biotechnology, exploring multiomics, the skin microbiome, bioengineered actives and the evidence the market now demands. About the event Where ingredient innovation meets the evidence behind it Sequential is bringing together senior R&D, innovation and scientific leaders from across the beauty, personal care and biotechnology industries for an exclusive full-day event on the future of next-generation ingredient innovation and validation. Expect sharp, practical talks, a moderated roundtable and time to connect with peers. FORMAT: Talks · Panel · Roundtable AUDIENCE: Senior R&D & Innovation Leaders VENUE: Attenborough Room, The Mills Fabrica, London Voices From Across the Industry Lieve Declercq Proya Cosmetics Regenerative biotechnology, a biomimetic Collagen XVII platform, and the future of global R&D collaboration between China and Europe. Dr. Albert Dashi Sequential Chief Science Officer & Co-founder. Behind the science: how Sequential validates next-generation ingredient claims. John Milligan The Honey Pot Company Destigmatizing intimate health and formulating for the fast-growing women’s health category. Christina Patane Medik8 Longevity, the skin microbiome, and Medik8’s five-year innovation roadmap. Martin Pagac DSM-Firmenich 3D facial microbiome mapping and the emerging role of human milk oligosaccharides (HMOs) in skin health. Veronika Oudova S-Biomedic Building the live skin probiotic category, the founder’s journey from idea to market. Dr. Amir Jassim AI Specialist Formerly University of Cambridge & Cancer Research UK. A fast-paced look at where AI is accelerating discovery and validation. On the day Thursday 3 December, 9:00am – 4:30pm Attenborough Room, The Mills Fabrica, London. Timings may shift slightly as the programme is finalised. 9:00am Registration & arrival coffee 10:00am Welcome & introduction to Sequential 10:15am Keynote: Dr. Lieve Declercq — Proya Chief Scientific Advisor & VP of European Innovation From Frontier Skin Science to Breakthrough Beauty Innovation 10:45am Cristina Patane — Medik8 Senior Formulation Scientist (Futures) Blue-Sky Beauty 11:10am Martin Pagac — dsm-firmenich Senior Scientist, PhD, Skin Biology Mapping and Modulating the Skin Microbiome 11:35am Coffee break 12:05pm Dr. Albert Dashi — Sequential Chief Science Officer & Co-founder Building the Clinical Testing Engine 12:30pm John Milligan — The Honey Pot Company VP R&D Women’s Health with Next-Generation Ingredients & Validation 12:55pm Veronika Oudova — S-Biomedic (Beiersdorf) Co-founder From Concept to Shelf 1:20pm Lunch break 1:50pm Science & Marketing Story Workshop 2:50pm Dr. Amir Jassim — AI Specialist Formerly University of Cambridge & Cancer Research UK AI in Ingredient Discovery 3:15pm Francisco González — Cobiosa R&D Director Skin Longevity: Bridging Science, Evidence and Innovation 3:40pm Dr. Ramdane Haddouche — Croda Research and Technology Specialist Topic to be announced 4:05 pm Roundtable discussion with the day’s speakers 4:25pm Networking break & cocktail hour at the pub (until 7pm)


